Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aß pathology.

Alzheimer Disease / genetics Amyloid beta-Protein Precursor / genetics Animals Astrocytes / cytology Brain / metabolism Disease Models, Animal Female Gene Expression Profiling Gene Expression Regulation Homozygote Humans Mice Mice, Transgenic NF-E2-Related Factor 2 / genetics Neuroprotection / genetics Phenotype Phosphorylation Proteostasis / genetics Proto-Oncogene Proteins / genetics Signal Transduction Trans-Activators / genetics tau Proteins / genetics

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
10 01 2022
Historique:
received: 24 07 2020
accepted: 06 12 2021
entrez: 11 1 2022
pubmed: 12 1 2022
medline: 27 1 2022
Statut: epublish

Résumé

Alzheimer's disease (AD) alters astrocytes, but the effect of Aß and Tau pathology is poorly understood. TRAP-seq translatome analysis of astrocytes in APP/PS1 ß-amyloidopathy and MAPT

Identifiants

DOI: 10.1038/s41467-021-27702-w PMID: 35013236 PMC: PMC8748982
pubmed: 35013236
doi: 10.1038/s41467-021-27702-w
pii: 10.1038/s41467-021-27702-w
pmc: PMC8748982
doi:

Substances chimiques

APP protein, mouse 0
Amyloid beta-Protein Precursor 0
Mapt protein, mouse 0
NF-E2-Related Factor 2 0
Nfe2l2 protein, mouse 0
Proto-Oncogene Proteins 0
Trans-Activators 0
proto-oncogene protein Spi-1 0
tau Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

135

Subventions

Organisme : Medical Research Council
ID : MC_PC_17113
Pays : United Kingdom
Organisme : National Centre for the Replacement, Refinement and Reduction of Animals in Research
ID : NC/N001419/1
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : PCL/20/05
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_EX_MR/N50192X/1
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : P50 AG033514
Pays : United States
Organisme : Medical Research Council
ID : MR/N013255/1
Pays : United Kingdom

Informations de copyright

© 2022. The Author(s).

Références

Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 8, 595–608 (2016).
pubmed: 27025652 pmcid: 4888851 doi: 10.15252/emmm.201606210
De Strooper, B. & Karran, E. The cellular phase of Alzheimer’s disease. Cell 164, 603–615 (2016).
pubmed: 26871627 doi: 10.1016/j.cell.2015.12.056
Belanger, M., Allaman, I. & Magistretti, P. J. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab. 14, 724–738 (2011).
pubmed: 22152301 doi: 10.1016/j.cmet.2011.08.016
Burda, J. E. & Sofroniew, M. V. Reactive gliosis and the multicellular response to CNS damage and disease. Neuron 81, 229–248 (2014).
pubmed: 24462092 pmcid: 3984950 doi: 10.1016/j.neuron.2013.12.034
Mathys, H. et al. Single-cell transcriptomic analysis of Alzheimer’s disease. Nature 570, 332–337 (2019).
pubmed: 31042697 pmcid: 6865822 doi: 10.1038/s41586-019-1195-2
Sekar, S. et al. Alzheimer’s disease is associated with altered expression of genes involved in immune response and mitochondrial processes in astrocytes. Neurobiol. Aging 36, 583–591 (2015).
pubmed: 25448601 doi: 10.1016/j.neurobiolaging.2014.09.027
Grubman, A. et al. A single-cell atlas of entorhinal cortex from individuals with Alzheimer’s disease reveals cell-type-specific gene expression regulation. Nat. Neurosci. 22, 2087–2097 (2019).
pubmed: 31768052 doi: 10.1038/s41593-019-0539-4
Carter, S. F. et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J. Nucl. Med. 53, 37–46 (2012).
pubmed: 22213821 doi: 10.2967/jnumed.110.087031
Escartin, C. et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat. Neurosci. 24, 312–325 (2021).
pubmed: 33589835 pmcid: 8007081 doi: 10.1038/s41593-020-00783-4
Allen, B. et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 22, 9340–9351 (2002).
pubmed: 12417659 pmcid: 6758022 doi: 10.1523/JNEUROSCI.22-21-09340.2002
Hampton, D. W. et al. Cell-mediated neuroprotection in a mouse model of human tauopathy. J. Neurosci. 30, 9973–9983 (2010).
pubmed: 20668182 pmcid: 6633376 doi: 10.1523/JNEUROSCI.0834-10.2010
Torvell, M. et al. A single systemic inflammatory insult causes acute motor deficits and accelerates disease progression in a mouse model of human tauopathy. Alzheimers Dement. 5, 579–591 (2019).
doi: 10.1016/j.trci.2019.09.001
Jankowsky, J. L. et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 13, 159–170 (2004).
pubmed: 14645205 doi: 10.1093/hmg/ddh019
Garcia-Alloza, M. et al. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 24, 516–524 (2006).
pubmed: 17029828 doi: 10.1016/j.nbd.2006.08.017
Janus, C., Flores, A. Y., Xu, G. & Borchelt, D. R. Behavioral abnormalities in APPSwe/PS1dE9 mouse model of AD-like pathology: comparative analysis across multiple behavioral domains. Neurobiol. Aging 36, 2519–2532 (2015).
pubmed: 26089165 doi: 10.1016/j.neurobiolaging.2015.05.010
Kamphuis, W. et al. GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS ONE 7, e42823 (2012).
pubmed: 22912745 pmcid: 3418292 doi: 10.1371/journal.pone.0042823
Doyle, J. P. et al. Application of a translational profiling approach for the comparative analysis of CNS cell types. Cell 135, 749–762 (2008).
pubmed: 19013282 pmcid: 2763427 doi: 10.1016/j.cell.2008.10.029
Clarke, L. E. et al. Normal aging induces A1-like astrocyte reactivity. Proc. Natl Acad. Sci. USA 115, E1896–E1905 (2018).
pubmed: 29437957 pmcid: 5828643 doi: 10.1073/pnas.1800165115
Liddelow, S. A. et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. https://doi.org/10.1038/nature21029nature21029[pii] (2017).
Zamanian, J. L. et al. Genomic analysis of reactive astrogliosis. J. Neurosci. 32, 6391–6410 (2012).
pubmed: 22553043 pmcid: 3480225 doi: 10.1523/JNEUROSCI.6221-11.2012
Marioni, R. E. et al. GWAS on family history of Alzheimer’s disease. Transl. Psychiatry 8, 99 (2018).
pubmed: 29777097 pmcid: 5959890 doi: 10.1038/s41398-018-0150-6
Sierksma, A. et al. Novel Alzheimer risk genes determine the microglia response to amyloid-beta but not to TAU pathology. EMBO Mol. Med. 12, e10606 (2020).
pubmed: 31951107 pmcid: 7059012 doi: 10.15252/emmm.201910606
Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90–W97 (2016).
pubmed: 27141961 pmcid: 4987924 doi: 10.1093/nar/gkw377
Puente-Santamaria, L., Wasserman, W. W. & Del Peso, L. TFEA.ChIP: A tool kit for transcription factor binding site enrichment analysis capitalizing on ChIP-seq datasets. Bioinformatics. https://doi.org/10.1093/bioinformatics/btz573 (2019).
Pajares, M., Cuadrado, A. & Rojo, A. I. Modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases. Redox Biol. 11, 543–553 (2017).
pubmed: 28104575 pmcid: 5239825 doi: 10.1016/j.redox.2017.01.006
Kobayashi, E. H. et al. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat. Commun. 7, 11624 (2016).
pubmed: 27211851 pmcid: 4879264 doi: 10.1038/ncomms11624
Tebay, L. E. et al. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. Free Radic. Biol. Med. 88, 108–146 (2015).
pubmed: 26122708 pmcid: 4659505 doi: 10.1016/j.freeradbiomed.2015.06.021
Vargas, M. R., Johnson, D. A., Sirkis, D. W., Messing, A. & Johnson, J. A. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J. Neurosci. 28, 13574–13581 (2008).
pubmed: 19074031 pmcid: 2866507 doi: 10.1523/JNEUROSCI.4099-08.2008
Malhotra, D. et al. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 38, 5718–5734 (2010).
pubmed: 20460467 pmcid: 2943601 doi: 10.1093/nar/gkq212
Pi, J. et al. Deficiency in the nuclear factor E2-related factor-2 transcription factor results in impaired adipogenesis and protects against diet-induced obesity. J. Biol. Chem. 285, 9292–9300 (2010).
pubmed: 20089859 pmcid: 2838347 doi: 10.1074/jbc.M109.093955
Hirotsu, Y. et al. Nrf2-MafG heterodimers contribute globally to antioxidant and metabolic networks. Nucleic Acids Res. 40, 10228–10239 (2012).
pubmed: 22965115 pmcid: 3488259 doi: 10.1093/nar/gks827
Schafer, M. et al. Nrf2 links epidermal barrier function with antioxidant defense. EMBO Mol. Med. 4, 364–379 (2012).
pubmed: 22383093 pmcid: 3403295 doi: 10.1002/emmm.201200219
Xu, J. et al. Deficiency in Nrf2 transcription factor decreases adipose tissue mass and hepatic lipid accumulation in leptin-deficient mice. Obesity 23, 335–344 (2015).
pubmed: 25451536 doi: 10.1002/oby.20929
Gomez, J. C., Dang, H., Martin, J. R. & Doerschuk, C. M. Nrf2 modulates host defense during Streptococcus pneumoniae pneumonia in mice. J. Immunol. 197, 2864–2879 (2016).
pubmed: 27566827 doi: 10.4049/jimmunol.1600043
Trio, P. Z. et al. DNA microarray highlights Nrf2-mediated neuron protection targeted by Wasabi-derived isothiocyanates in IMR-32 Cells. Gene Regul. Syst. Biol. 10, 73–83 (2016).
Sun, W. et al. SOX9 is an astrocyte-specific nuclear marker in the adult brain outside the neurogenic regions. J. Neurosci. 37, 4493–4507 (2017).
pubmed: 28336567 pmcid: 5413187 doi: 10.1523/JNEUROSCI.3199-16.2017
Bell, K. F. et al. Neuronal development is promoted by weakened intrinsic antioxidant defences due to epigenetic repression of Nrf2. Nat. Commun. 6, 7066 (2015).
pubmed: 25967870 doi: 10.1038/ncomms8066
Qiu, J. et al. Mixed-species RNA-seq for elucidating non-cell-autonomous control of gene transcription. Nat. Protoc. 13, 2176–2199 (2018).
pubmed: 30250293 doi: 10.1038/s41596-018-0029-2
Judge, M., Hornbeck, L., Potter, H. & Padmanabhan, J. Mitosis-specific phosphorylation of amyloid precursor protein at threonine 668 leads to its altered processing and association with centrosomes. Mol. Neurodegener. 6, 80 (2011).
pubmed: 22112898 pmcid: 3284477 doi: 10.1186/1750-1326-6-80
Bassil, F. et al. Amyloid-beta (Abeta) plaques promote seeding and spreading of alpha-synuclein and tau in a mouse model of lewy body disorders with abeta pathology. Neuron 105, 260–275 e266 (2020).
pubmed: 31759806 doi: 10.1016/j.neuron.2019.10.010
Hofling, C. et al. Differential transgene expression patterns in Alzheimer mouse models revealed by novel human amyloid precursor protein-specific antibodies. Aging Cell 15, 953–963 (2016).
pubmed: 27470171 pmcid: 5013031 doi: 10.1111/acel.12508
Rahman, M. A. et al. Modulatory effects of autophagy on APP processing as a potential treatment target for Alzheimer’s disease. Biomedicines 9. https://doi.org/10.3390/biomedicines9010005 (2020).
Spilman, P. et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer’s disease. PLoS ONE 5, e9979 (2010).
pubmed: 20376313 pmcid: 2848616 doi: 10.1371/journal.pone.0009979
Yang, D. S. et al. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer’s disease ameliorates amyloid pathologies and memory deficits. Brain 134, 258–277 (2011).
pubmed: 21186265 doi: 10.1093/brain/awq341
Caccamo, A., Majumder, S., Richardson, A., Strong, R. & Oddo, S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and tau: effects on cognitive impairments. J. Biol. Chem. 285, 13107–13120 (2010).
pubmed: 20178983 pmcid: 2857107 doi: 10.1074/jbc.M110.100420
Thal, D. R. The role of astrocytes in amyloid beta-protein toxicity and clearance. Exp. Neurol. 236, 1–5 (2012).
pubmed: 22575598 doi: 10.1016/j.expneurol.2012.04.021
Heneka, M. T. et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 14, 388–405 (2015).
pubmed: 25792098 pmcid: 5909703 doi: 10.1016/S1474-4422(15)70016-5
Lin, M. T. & Beal, M. F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787–795 (2006).
pubmed: 17051205 doi: 10.1038/nature05292
Tang, B. L. Glucose, glycolysis, and neurodegenerative diseases. J Cell Physiol, https://doi.org/10.1002/jcp.29682 (2020).
Ma, T. et al. Suppression of eIF2alpha kinases alleviates Alzheimer’s disease-related plasticity and memory deficits. Nat. Neurosci. 16, 1299–1305 (2013).
pubmed: 23933749 pmcid: 3756900 doi: 10.1038/nn.3486
Spires-Jones, T. L. & Hyman, B. T. The intersection of amyloid beta and tau at synapses in Alzheimer’s disease. Neuron 82, 756–771 (2014).
pubmed: 24853936 pmcid: 4135182 doi: 10.1016/j.neuron.2014.05.004
Pekny, M. et al. Astrocytes: a central element in neurological diseases. Acta Neuropathol. 131, 323–345 (2016).
pubmed: 26671410 doi: 10.1007/s00401-015-1513-1
Liddelow, S. A. & Barres, B. A. Reactive astrocytes: production, function, and therapeutic potential. Immunity 46, 957–967 (2017).
pubmed: 28636962 doi: 10.1016/j.immuni.2017.06.006
Das, S., Li, Z., Noori, A., Hyman, B. T. & Serrano-Pozo, A. Meta-analysis of mouse transcriptomic studies supports a context-dependent astrocyte reaction in acute CNS injury versus neurodegeneration. J. Neuroinflammation. 17, 227 (2020).
pubmed: 32736565 pmcid: 7393869 doi: 10.1186/s12974-020-01898-y
Diaz-Castro, B., Gangwani, M. R., Yu, X., Coppola, G. & Khakh, B. S. Astrocyte molecular signatures in Huntington’s disease. Sci. Transl. Med. 11. https://doi.org/10.1126/scitranslmed.aaw8546 (2019).
Toepper, M. Dissociating normal aging from Alzheimer’s disease: a view from cognitive neuroscience. J. Alzheimers Dis. 57, 331–352 (2017).
pubmed: 28269778 pmcid: 5366251 doi: 10.3233/JAD-161099
Qiu, J. et al. Evidence for evolutionary divergence of activity-dependent gene expression in developing neurons. Elife 5, https://doi.org/10.7554/eLife.20337e20337[pii] (2016).
Hardingham, G. E., Pruunsild, P., Greenberg, M. E. & Bading, H. Lineage divergence of activity-driven transcription and evolution of cognitive ability. Nat. Rev. Neurosci. 19, 9–15 (2018).
pubmed: 29167525 doi: 10.1038/nrn.2017.138
Zhou, Y. et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease. Nat. Med. 26, 131–142 (2020).
pubmed: 31932797 pmcid: 6980793 doi: 10.1038/s41591-019-0695-9
Pickett, E. K. et al. Amyloid beta and tau cooperate to cause reversible behavioral and transcriptional deficits in a model of Alzheimer’s disease. Cell Rep. 29, 3592–3604 e3595 (2019).
pubmed: 31825838 pmcid: 6915767 doi: 10.1016/j.celrep.2019.11.044
SantaCruz, K. S., Yazlovitskaya, E., Collins, J., Johnson, J. & DeCarli, C. Regional NAD(P)H:quinone oxidoreductase activity in Alzheimer’s disease. Neurobiol. Aging 25, 63–69 (2004).
pubmed: 14675732 doi: 10.1016/S0197-4580(03)00117-9
Schipper, H. M. et al. Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol. Aging 27, 252–261 (2006).
pubmed: 16399210 doi: 10.1016/j.neurobiolaging.2005.01.016
Chetelat, G. et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer’s disease. Neuroimage Clin. 2, 356–365 (2013).
pubmed: 24179789 pmcid: 3777672 doi: 10.1016/j.nicl.2013.02.006
Rojo, R. et al. Deletion of a Csf1r enhancer selectively impacts CSF1R expression and development of tissue macrophage populations. Nat. Commun. 10, 3215 (2019).
pubmed: 31324781 pmcid: 6642117 doi: 10.1038/s41467-019-11053-8
Canals, S., Larrosa, B., Pintor, J., Mena, M. A. & Herreras, O. Metabolic challenge to glia activates an adenosine-mediated safety mechanism that promotes neuronal survival by delaying the onset of spreading depression waves. J. Cereb. Blood Flow. Metab. 28, 1835–1844 (2008).
pubmed: 18612316 doi: 10.1038/jcbfm.2008.71
Park, S. A., Han, S. M. & Kim, C. E. New fluid biomarkers tracking non-amyloid-beta and non-tau pathology in Alzheimer’s disease. Exp. Mol. Med. 52, 556–568 (2020).
pubmed: 32284537 pmcid: 7210893 doi: 10.1038/s12276-020-0418-9
Ishiki, A. et al. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. J. Neurochem. 136, 258–261 (2016).
pubmed: 26485083 doi: 10.1111/jnc.13399
Goetzl, E. J., Schwartz, J. B., Abner, E. L., Jicha, G. A. & Kapogiannis, D. High complement levels in astrocyte-derived exosomes of Alzheimer disease. Ann. Neurol. 83, 544–552 (2018).
pubmed: 29406582 pmcid: 5867263 doi: 10.1002/ana.25172
Winston, C. N., Goetzl, E. J., Schwartz, J. B., Elahi, F. M. & Rissman, R. A. Complement protein levels in plasma astrocyte-derived exosomes are abnormal in conversion from mild cognitive impairment to Alzheimer’s disease dementia. Alzheimers Dement. 11, 61–66 (2019).
Hardingham, G. E. & Lipton, S. A. Regulation of neuronal oxidative and nitrosative stress by endogenous protective pathways and disease processes. Antioxid. Redox Signal. 14, 1421–1424 (2011).
pubmed: 20977364 doi: 10.1089/ars.2010.3573
Vargas, M. R. & Johnson, J. A. The Nrf2-ARE cytoprotective pathway in astrocytes. Expert Rev. Mol. Med. 11, e17 (2009).
pubmed: 19490732 pmcid: 5563256 doi: 10.1017/S1462399409001094
Shih, A. Y. et al. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J. Neurosci. 23, 3394–3406 (2003).
pubmed: 12716947 pmcid: 6742304 doi: 10.1523/JNEUROSCI.23-08-03394.2003
Baxter, P. S. et al. Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system. Nat. Commun. 6, 6761 (2015).
pubmed: 25854456 doi: 10.1038/ncomms7761
Bell, K. F. & Hardingham, G. E. The influence of synaptic activity on neuronal health. Curr. Opin. Neurobiol. 21, 299–305 (2011).
pubmed: 21292474 pmcid: 3160470 doi: 10.1016/j.conb.2011.01.002
Levy, E. et al. Causative links between protein aggregation and oxidative stress: a review. Int. J. Mol. Sci. 20. https://doi.org/10.3390/ijms20163896 (2019).
Lee, S. et al. Involvement of the Nrf2-proteasome pathway in the endoplasmic reticulum stress response in pancreatic beta-cells. Toxicol. Appl Pharmacol. 264, 431–438 (2012).
pubmed: 22959925 doi: 10.1016/j.taap.2012.08.021
Cullinan, S. B. et al. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol. Cell Biol. 23, 7198–7209 (2003).
pubmed: 14517290 pmcid: 230321 doi: 10.1128/MCB.23.20.7198-7209.2003
Zanotto-Filho, A. et al. Alkylating agent-induced NRF2 blocks endoplasmic reticulum stress-mediated apoptosis via control of glutathione pools and protein thiol homeostasis. Mol. Cancer Ther 15, 3000–3014 (2016).
pubmed: 27638861 pmcid: 5136348 doi: 10.1158/1535-7163.MCT-16-0271
Hohn, A., Tramutola, A. & Cascella, R. Proteostasis failure in neurodegenerative diseases: focus on oxidative stress. Oxid. Med Cell Longev. 2020, 5497046 (2020).
pubmed: 32308803 pmcid: 7140146 doi: 10.1155/2020/5497046
Alavi Naini, S. M. & Soussi-Yanicostas, N. Tau hyperphosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies? Oxid. Med Cell Longev. 2015, 151979 (2015).
pubmed: 26576216 pmcid: 4630413 doi: 10.1155/2015/151979
Gan, L., Vargas, M. R., Johnson, D. A. & Johnson, J. A. Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model. J. Neurosci. 32, 17775–17787 (2012).
pubmed: 23223297 pmcid: 3539799 doi: 10.1523/JNEUROSCI.3049-12.2012
Borchelt, D. R. et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939–945 (1997).
pubmed: 9354339 doi: 10.1016/S0896-6273(00)80974-5
Jankowsky, J. L. et al. Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development. Curr. Neurol. Neurosci. Rep. 2, 457–464 (2002).
pubmed: 12169227 doi: 10.1007/s11910-002-0073-7
Hasel, P. et al. Neurons and neuronal activity control gene expression in astrocytes to regulate their development and metabolism. Nat. Commun. 8, 15132 (2017).
pubmed: 28462931 pmcid: 5418577 doi: 10.1038/ncomms15132
Heiman, M., Kulicke, R., Fenster, R. J., Greengard, P. & Heintz, N. Cell type-specific mRNA purification by translating ribosome affinity purification (TRAP). Nat. Protoc. 9, 1282–1291 (2014).
pubmed: 24810037 pmcid: 4102313 doi: 10.1038/nprot.2014.085
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886 doi: 10.1093/bioinformatics/bts635
Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).
pubmed: 24227677 doi: 10.1093/bioinformatics/btt656
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281 pmcid: 4302049 doi: 10.1186/s13059-014-0550-8
Puddifoot, C. et al. PGC-1alpha negatively regulates extrasynaptic NMDAR activity and excitotoxicity. J. Neurosci. 32, 6995–7000 (2012).
pubmed: 22593067 pmcid: 3359835 doi: 10.1523/JNEUROSCI.6407-11.2012
Cunningham, C. et al. Neuropathologically distinct prion strains give rise to similar temporal profiles of behavioral deficits. Neurobiol. Dis. 18, 258–269 (2005).
pubmed: 15686954 doi: 10.1016/j.nbd.2004.08.015
Koffie, R. M. et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl Acad. Sci. USA 106, 4012–4017 (2009).
pubmed: 19228947 pmcid: 2656196 doi: 10.1073/pnas.0811698106

Auteurs

Zoeb Jiwaji (Z)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.
Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8 9XD, UK.
ORCID: 0000-0002-3129-1168

Sachin S Tiwari (SS)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.
Centre for Clinical Brain Sciences, University of Edinburgh Chancellor's Building, Edinburgh, UK.

Rolando X Avilés-Reyes (RX)

Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA.

Monique Hooley (M)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.
Centre for Clinical Brain Sciences, University of Edinburgh Chancellor's Building, Edinburgh, UK.

David Hampton (D)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.
Centre for Clinical Brain Sciences, University of Edinburgh Chancellor's Building, Edinburgh, UK.

Megan Torvell (M)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.
Centre for Clinical Brain Sciences, University of Edinburgh Chancellor's Building, Edinburgh, UK.
UK Dementia Research Institute at Cardiff University, Hadyn Ellis Building, Cardiff, CF24 4HQ, UK.
ORCID: 0000-0003-3789-1452

Delinda A Johnson (DA)

Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA.

Jamie McQueen (J)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.
Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8 9XD, UK.
ORCID: 0000-0001-7172-7504

Paul Baxter (P)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.
Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8 9XD, UK.

Kayalvizhi Sabari-Sankar (K)

Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA.

Jing Qiu (J)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.
Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8 9XD, UK.

Xin He (X)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.
Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8 9XD, UK.

Jill Fowler (J)

Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8 9XD, UK.

James Febery (J)

Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8 9XD, UK.

Jenna Gregory (J)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.
Centre for Clinical Brain Sciences, University of Edinburgh Chancellor's Building, Edinburgh, UK.
ORCID: 0000-0003-3337-4079

Jamie Rose (J)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.
Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8 9XD, UK.

Jane Tulloch (J)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.
Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8 9XD, UK.

Jamie Loan (J)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.
Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8 9XD, UK.
ORCID: 0000-0002-6451-9448

David Story (D)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.
Centre for Clinical Brain Sciences, University of Edinburgh Chancellor's Building, Edinburgh, UK.

Karina McDade (K)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.

Amy M Smith (AM)

UK Dementia Research Institute at Imperial College, Burlington Danes Building, Hammersmith Hospital, London, W12 0NN, UK.

Peta Greer (P)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.
Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8 9XD, UK.

Matthew Ball (M)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.
Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8 9XD, UK.

Peter C Kind (PC)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.
Simons Initiative for the Developing Brain, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8 9XD, UK.

Paul M Matthews (PM)

UK Dementia Research Institute at Imperial College, Burlington Danes Building, Hammersmith Hospital, London, W12 0NN, UK.
ORCID: 0000-0002-1619-8328

Colin Smith (C)

Centre for Clinical Brain Sciences, University of Edinburgh Chancellor's Building, Edinburgh, UK.

Owen Dando (O)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.
Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8 9XD, UK.
Simons Initiative for the Developing Brain, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8 9XD, UK.
ORCID: 0000-0002-6269-6408

Tara L Spires-Jones (TL)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK.
Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8 9XD, UK.
ORCID: 0000-0003-2530-0598

Jeffrey A Johnson (JA)

Division of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA. jeffrey.johnson@wisc.edu.
ORCID: 0000-0002-3315-7210

Siddharthan Chandran (S)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK. Siddharthan.Chandran@ed.ac.uk.
Centre for Clinical Brain Sciences, University of Edinburgh Chancellor's Building, Edinburgh, UK. Siddharthan.Chandran@ed.ac.uk.

Giles E Hardingham (GE)

UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh Medical School, Edinburgh, EH16 4SB, UK. Giles.Hardingham@ed.ac.uk.
Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh, EH8 9XD, UK. Giles.Hardingham@ed.ac.uk.
ORCID: 0000-0002-7629-5314

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines sécrétoires inhibitrices de protéinases › Protéase nexines › Précurseur de la protéine bêta-amyloïde › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Eucaryotes › Animaux › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Cellules › Névroglie › Astrocytes › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Analyse de profil d'expression de gènes › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Phénomènes génétiques › Génotype › Homozygote › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souris transgéniques › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription à motif basique et à glissière à leucines › Facteur-2 apparenté à NF-E2 › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système nerveux › Neuroprotection › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Phénomènes génétiques › Phénotype › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Métabolisme › Phosphorylation › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Métabolisme › Homéostasie protéique › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales régulatrices ou accessoires › Transactivateurs › Reactive astrocytes acquire neuroprotective as...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de tissu nerveux › Protéines associées aux microtubules › Protéines tau › Reactive astrocytes acquire neuroprotective as...